

Se Hoon Park

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/40718/se-hoon-park-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

242
papers

6,188
citations

32
h-index

74
g-index

252
ext. papers

8,157
ext. citations

4.7
avg, IF

5.38
L-index

#	Paper	IF	Citations
242	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).. <i>Gastric Cancer</i> , 2022 , 1	7.6	1
241	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	5
240	Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.. <i>Investigative and Clinical Urology</i> , 2022 , 63, 168-174	1.9	1
239	First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 432-432	2.2	0
238	Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 551-551	2.2	
237	A prospective phase II trial of neoadjuvant nivolumab plus gemcitabine/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of bladder.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 494-494	2.2	0
236	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing.. <i>Journal of Oncology</i> , 2022 , 2022, 9714570	4.5	0
235	Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.. <i>Current Problems in Cancer</i> , 2022 , 46, 100848	2.3	0
234	A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.. <i>Frontiers in Oncology</i> , 2022 , 12, 874385	5.3	
233	Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022 , 14, 2354	6.6	0
232	Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer.. <i>Cancers</i> , 2021 , 13,	6.6	4
231	A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer. <i>BMC Cancer</i> , 2021 , 21, 1281	4.8	1
230	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4700-4709	12.9	17
229	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021 , 36, 491-514	2.5	0
228	Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4524-4524	2.2	0
227	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4056-4056	2.2	1
226	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 2102-2114	59.2	83

225	Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130 2021 ,		3
224	Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center. <i>Cancer Research and Treatment</i> , 2021 , 53, 874-880	5.2	0
223	Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130 2021 ,		2
222	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021 , 112, 305-313	6.9	10
221	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021 , 99, 365-372	3.6	2
220	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021 , 12, 460-466 ^{4.5}		2
219	EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 394-394	2.2	8
218	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	
217	Reducing tumor invasiveness by ramucirumab and TGF- β receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model. <i>Cancer Medicine</i> , 2021 , 10, 7253-7262	4.8	1
216	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835921992992	5.4	11
215	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920965842	5.4	3
214	Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. <i>Genome Medicine</i> , 2020 , 12, 47	14.4	45
213	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.. <i>Translational Cancer Research</i> , 2020 , 9, 3367-3374	0.3	4
212	Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>JCO Global Oncology</i> , 2020 , 6, 414-438	3.7	42
211	A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring Mutations. <i>Clinical Cancer Research</i> , 2020 , 26, 5113-5119	12.9	14
210	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. <i>Lancet Oncology</i> , 2020 , 21, 1066-1076	21.7	60
209	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020 , 216, 152820	3.4	2
208	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020 , 2020, 4659062	4.5	2

207	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. <i>Pathology Research and Practice</i> , 2020 , 216, 152881	3.4	22
206	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020 , 12, 17	14.4	8
205	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020 , 15, 185-192	5	1
204	Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. <i>ESMO Open</i> , 2020 , 5,	6	10
203	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
202	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
201	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 314	5.3	31
200	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5015-5015	2.2	10
199	Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6504-6504	2.2	16
198	Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 527-527	2.2	2
197	Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS256-TPS256	2.2	9
196	A clinical scoring system for survival prediction in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 436-436	2.2	
195	Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. <i>Cancers</i> , 2020 , 13,	6.6	4
194	Multiple Opportunistic Infections Related to Hypercortisolemia due to Adrenocortical Carcinoma: A Case Report. <i>Infection and Chemotherapy</i> , 2020 ,	3.9	1
193	PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16679-e16679	2.2	
192	Phase II study of biweekly docetaxel plus androgen-deprivation therapy (ADT) in patients with previously-untreated, metastatic, prostatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17580-e17580	2.2	22
191	Tipifarnib, a farnesyltransferase inhibitor, for metastatic urothelial carcinoma harboring HRAS mutations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5086-5086	2.2	
190	Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy Followed by Radical Cystectomy: A Single-Center Retrospective Study. <i>The Korean Journal of Urological Oncology</i> , 2020 , 18, 194-200	0.1	

189	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study. <i>Investigative and Clinical Urology</i> , 2020 , 61, 588-593	1.9	0
188	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 395-405	2.2	216
187	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1045-1056	21.7	16
186	Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis. <i>Journal of Cancer</i> , 2020 , 11, 7202-7208	4.5	0
185	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. <i>Radiotherapy and Oncology</i> , 2020 , 152, 19-25	5.3	2
184	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920926796	5.4	5
183	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in -Amplified Gastric Cancer. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	7
182	Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e1137-e1146	3.3	2
181	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019 , 12, 597-601	4.9	5
180	A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer. <i>BMC Urology</i> , 2019 , 19, 30	2.2	4
179	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019 , 97, 38-43	3.6	14
178	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019 , 10, 1611-1615	4.5	4
177	Bridging genomics and phenomics of gastric carcinoma. <i>International Journal of Cancer</i> , 2019 , 145, 2407-2417	7.5	25
176	Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , 2019 , 20, 1454-1466	21.7	66
175	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. <i>Journal of Cancer</i> , 2019 , 10, 3172-3178	4.5	1
174	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019 , 10, 3140-3144	4.5	3
173	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019 , 9, 1388-1405	24.4	78
172	Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03. <i>Cancer Medicine</i> , 2019 , 8, 5131-5137	4.8	8

171	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (≥5 Years) With Gastric Cancer. <i>Anticancer Research</i> , 2019 , 39, 5811-5820	2.3	4
170	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3104-3104	2.2	1
169	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4001-4001	2.2	42
168	Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4547-4547	2.2	2
167	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, LBA3-LBA3	2.2	38
166	Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 65-65	2.2	13
165	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , 2019 , 11, 4508-4515	3	2
164	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019 , 51, 876-885	5.2	5
163	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 213-213	2.2	
162	Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4064-4064	2.2	
161	Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4543-4543	2.2	0
160	Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3023-3023	2.2	1
159	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs.. <i>Translational Cancer Research</i> , 2019 , 8, 2107-2112	0.3	
158	Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study. <i>Cancer Research and Treatment</i> , 2019 , 51, 1269-1274	5.2	1
157	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019 , 11,	6.6	13
156	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. <i>Frontiers in Oncology</i> , 2019 , 9, 1327	5.3	5
155	Role of Adjuvant Chemotherapy in Advanced Stage Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: Competing Risk Analysis after Propensity Score-Matching. <i>Journal of Cancer</i> , 2019 , 10, 6896-6902	4.5	3
154	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 501-508	3.5	5

153	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019 , 12, 225-231	4.4	4
152	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 140-146	3.8	11
151	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 165-169	3.8	44
150	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018 , 11, 353-357	4.9	6
149	Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy. <i>Journal of Urology</i> , 2018 , 200, 989-995	2.5	7
148	Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. <i>BMC Urology</i> , 2018 , 18, 68	2.2	12
147	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2018 , 9, 1791-1796	4.5	5
146	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018 , 129, 306-312	5.3	11
145	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e3	4	10
144	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018 , 24, 1449-1458	50.5	577
143	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018 , 95, 344-352	3.6	9
142	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018 , 9, 2910-2915	4.5	5
141	Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4021-4021	2.2	1
140	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatred gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4061-4061	2.2	1
139	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4503-4503	2.2	42
138	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14501-e14501	2.2	1
137	Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16029-e16029	2.2	1
136	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4599-TPS4599	2.2	11

135	Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 411-411	2.2	21
134	Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 494-494	2.2	15
133	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS712-TPS712	2.2	4
132	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <i>Cancer Research and Treatment</i> , 2018 , 50, 488-494	5.2	20
131	Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). <i>Cancer Research and Treatment</i> , 2018 , 50, 1252-1259	5.2	20
130	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24234-e24234	2.2	
129	Detection of targetable fusions using FusionPlex in oncology patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24238-e24238	2.2	
128	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. <i>Translational Oncology</i> , 2018 , 11, 37-42	4.9	22
127	Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-14	5.2	11
126	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018 , 18, 1103	4.8	15
125	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018 , 18, 348-355	3.2	8
124	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , 2018 , 9, 3394-3399	4.5	4
123	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 663-669	8.7	48
122	Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2018 , 25, 596-603	2.3	12
121	Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 61-67	1.9	14
120	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. <i>Journal of Geriatric Oncology</i> , 2017 , 8, 170-175	3.6	26
119	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 782-790	4.3	17
118	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. <i>Translational Oncology</i> , 2017 , 10, 469-475	4.9	21

117	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , 2017 , 17, 211	4.8	21
116	Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2017 , 10, 304-310	4.9	2
115	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1637-1651	21.7	174
114	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). <i>Journal of Cancer</i> , 2017 , 8, 1395-1399	4.5	17
113	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2809-2815	4.5	10
112	Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. <i>Oncotarget</i> , 2017 , 8, 15014-15022	3.3	32
111	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	18
110	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017 , 8, 11094-11104	3.3	15
109	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017 , 8, 77415-77423	3.3	55
108	A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. <i>BMC Urology</i> , 2017 , 17, 63	2.2	5
107	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. <i>Oncolimmunology</i> , 2017 , 6, e1356150	7.2	27
106	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , 2017 , 22, 1169-1177	5.7	10
105	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 27-31	1.6	13
104	Molecular characterization of urothelial carcinoma of bladder and upper urinary tract.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 361-361	2.2	1
103	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017 , 8, 3237-3245	3.3	13
102	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , 2017 , 8, 13320-13328	3.3	50
101	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. <i>Oncotarget</i> , 2017 , 8, 42478-42486	3.3	16
100	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , 2017 , 8, 73974-73980	3.3	3

99	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. <i>Oncotarget</i> , 2017 , 8, 107492-107499	3.3	5
98	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. <i>Oncotarget</i> , 2017 , 8, 66305-66315	3.3	19
97	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017 , 8, 105727-105734	3.3	12
96	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017 , 8, 96656-96667	3.3	17
95	A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2017 , 49, 816-823	5.2	8
94	Overall survival beyond first-line docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e570-e570	2.2	1
93	Development of a novel patient-derived preclinical model from malignant effusions in patients with tyrosine kinase inhibitor resistant clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 445-445	2.2	
92	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14622-e14622	2.2	
91	VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4024-4024	2.2	1
90	Critical role of XBP1 in cancer signalling is regulated by PIN1. <i>Biochemical Journal</i> , 2016 , 473, 2603-10	3.8	14
89	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. <i>BMC Urology</i> , 2016 , 16, 46	2.2	13
88	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. <i>ESMO Open</i> , 2016 , 1, e000009	6	13
87	A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma. <i>Clinical Sarcoma Research</i> , 2016 , 6, 8	2.5	7
86	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1231-7	4.9	10
85	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 76-81	3.3	8
84	First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2570-2570	2.2	4
83	Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4016-4016	2.2	3
82	Prognostic value of the metastatic lymph node (N) ratio in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) phase III trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4038-4038	2.2	1

81	Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4043-4043	2.2	10
80	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4557-4557	2.2	3
79	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016 , 7, 24088-96	3.3	9
78	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , 2016 , 34, 34-44	2.5	9
77	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016 , 48, 153-61	5.2	9
76	Current Status and Challenges of Cancer Clinical Trials in Korea. <i>Cancer Research and Treatment</i> , 2016 , 48, 20-7	5.2	9
75	Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis. <i>Cancer Research and Treatment</i> , 2016 , 48, 1274-1285	5.2	14
74	A retrospective feasibility analysis of biweekly reduced dose docetaxel in Korean patients with castration-resistant, metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e638-e638	2.2	
73	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 355-355	2.2	
72	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4091-4091	2.2	
71	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , 2016 , 7, 1044-8	4.5	13
70	Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer. <i>Journal of Cancer</i> , 2016 , 7, 1711-1715	4.5	6
69	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. <i>Journal of Cancer</i> , 2016 , 7, 2173-2178 ¹	4.5	1
68	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. <i>Journal of Cancer</i> , 2016 , 7, 1174-80	4.5	22
67	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016 , 48, 553-60	5.2	13
66	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016 , 16, 105-10	3.2	26
65	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , 2016 , 7, 43492-43503	3.3	37
64	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 979-85	3.5	22

63	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. <i>Modern Pathology</i> , 2016 , 29, 1095-103	9.8	49
62	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 375-83	4.5	12
61	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. <i>Translational Oncology</i> , 2016 , 9, 197-202	4.9	8
60	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3130-6	2.2	271
59	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nature Medicine</i> , 2015 , 21, 449-56	50.5	1031
58	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015 , 15, 530	4.8	15
57	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015 , 15, 154	4.8	46
56	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2015 , 117, 171-7	5.3	29
55	Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study. <i>BMC Palliative Care</i> , 2015 , 14, 41	3	10
54	HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. <i>International Journal of Cancer</i> , 2015 , 136, 1629-35	7.5	28
53	The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. <i>Scientific Reports</i> , 2015 , 5, 9289	4.9	33
52	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015 , 8, 288-94	4.9	7
51	Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <i>BMC Cancer</i> , 2015 , 15, 693	4.8	12
50	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015 , 15, 747	4.8	6
49	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015 , 6, 40360-9	3.3	77
48	Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015 , 30, e382-6	2.8	19
47	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015 , 6, 28211-22	3.3	48
46	Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 256-60	2.8	13

45	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2015 , 8, 40-6	4.9	14
44	Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 72-7	5.2	14
43	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2522-2522	2.2	1
42	First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4051-4051	2.2	3
41	The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid Tumors: cfDNA-Based Umbrella Trial, an interim analysis).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12540-e12540	2.2	1
40	Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS228-TPS228	2.2	4
39	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015 , 6, 25619-30	3.3	42
38	The NEXT-1 (Next generation pERsonalized tX with mULTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015 , 6, 33358-68	3.3	21
37	Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4268-74	5.6	7
36	The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. <i>Korean Journal of Internal Medicine</i> , 2015 , 30, 88-95	2.5	9
35	Do all patients with HER2-positive gastric/GEJ cancer benefit from trastuzumab?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 185-185	2.2	
34	Clinical features of metastatic renal cell carcinoma patients with intrinsic resistance to sunitinib: A Korean multicenter study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 462-462	2.2	
33	Clinicians? preference of adjuvant S-1 versus capecitabine plus oxaliplatin after curative gastrectomy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15025-e15025	2.2	
32	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4138-TPS4138	2.2	
31	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4049-4049	2.2	2
30	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3576-3576	2.2	
29	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN). <i>Journal of Clinical Oncology</i> , 2015 , 33, e22173-e22173	2.2	
28	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22241-e22241	2.2	

27	Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , 2014 , 50, 2822-30	7.5	52
26	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , 2014 , 4, 7592	4.9	21
25	Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2527-36	6.1	26
24	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. <i>Clinical Sarcoma Research</i> , 2014 , 4, 13	2.5	21
23	Second-line chemotherapy for patients with oesophagogastric adenocarcinoma. <i>Lancet Oncology, The</i> , 2014 , 15, 8-10	21.7	26
22	Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 158-158	2.2	1
21	High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. <i>PLoS ONE</i> , 2014 , 9, e111693	3.7	32
20	Chemotherapy in advanced gastric cancer patients associated with disseminated intravascular coagulation. <i>Cancer Research and Treatment</i> , 2014 , 46, 27-32	5.2	5
19	Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15106-e15106	2.2	
18	The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10586-10586	2.2	1
17	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4008-4008	2.2	
16	A retrospective, multicenter analysis of the clinicopathologic features of extra-gastrointestinal stromal tumor (EGIST).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 36-36	2.2	
15	Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 362-362	2.2	
14	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. <i>Anticancer Research</i> , 2014 , 34, 6585-91	2.3	2
13	Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. <i>PLoS ONE</i> , 2013 , 8, e82770	3.7	31
12	Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. <i>Cancer Research and Treatment</i> , 2013 , 45, 285-94	5.2	10
11	A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15613-e15613	2.2	
10	Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. <i>Cancer</i> , 2012 , 118, 2828-36	6.4	64

9	Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 268-73	2.2	537
8	Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1513-8	2.2	468
7	Perceptions of clinical trials in gastrointestinal/hepatobiliary cancer patients: A comprehensive survey in a Korean tertiary hospital.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13094-e13094	2.2	
6	Irinotecan and Cisplatin Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Patients with Limited Disease Small Cell Lung Cancer. <i>Journal of Lung Cancer</i> , 2011 , 10, 49		1
5	Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. <i>Oncology Reports</i> , 2011 , 25, 1517-24	3.5	99
4	In reply to Mauer et al. Statistical methodology is crucial in prognostic factor-analysis of health-related quality of life. <i>Quality of Life Research</i> , 2008 , 17, 1045-1046	3.7	
3	Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. <i>Cancer</i> , 2007 , 109, 732-40	6.4	21
2	The outcomes of hypertransfusion in major ABO incompatible allogeneic stem cell transplantation. <i>Journal of Korean Medical Science</i> , 2004 , 19, 79-82	4.7	2
1	Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 477-80	2.7	38